Pacira BioSciences, Inc. <PCRX.O>: Truist Securities reinstates coverage with buy rating; price target $30
PCRX•Related News
Dynatrace targets private placement of USD 1.25 billion exchangeable senior notes due 2031
DT•
Madison Air Solutions to buy Germany's ebm-papst in $5.4 billion deal
MAIR•
Pinnacle West Capital Corporation: Truist Securities cuts target price to $101 from $107
PNW•
Silver One posts corporate deck outlining path to Candelaria silver project development in Nevada
SIL•
Freightos IFRS loss narrows to USD 1.6 million in Q2 2026; revenue rises 3% to USD 7.7 million year-over-year
CRGO•